International research led by Italy paves the way for photocoxibs, molecules that can be activated by light directly in inflamed tissue. The objective is to reduce the side effects of common NSAIDs without sacrificing therapeutic efficacy.
For decades the non-steroidal anti-inflammatories (NSAIDs) they represent one of the pillars of modern medicine. Headaches, arthrosis, muscle pain, fever, sports injuries: millions of people take ibuprofen, naproxen, diclofenac or celecoxib every day, trusting in their ability to turn off pain and inflammation. The problem is as well known as these drugs themselves. NSAIDs do not perfectly distinguish diseased tissue from healthy tissue and, for this very reason, the therapeutic effect is often accompanied by a long list of unwanted effectsfrom gastric disorders to cardiovascular complications in prolonged treatments. For a long time, pharmacology has been looking for an apparently simple solution: maintaining effectiveness while eliminating toxicity as much as possible. An answer could come from a still young but rapidly growing sector, the photopharmacologya discipline that uses light as a real molecular switch to control the activity of a drug. The idea is as elegant as it is revolutionary: instead of distributing an active ingredient that acts everywhere in the organism, design molecules capable of becoming effective only when they are illuminated and only where intervention is needed. This perspective found concrete demonstration in an international study published on May 13, 2026 on the Journal of the American Chemical Society (JACS)coordinated byUniversity of Milan with the participation ofFederico II University of Naplesof theUniversitat Autònoma de Barcelona and of theInstitute for Bioengineering of Catalonia. The work represents one of the most advanced results obtained so far in the field of photoadjustable drugs and introduces a new family of named molecules photocoxib. The starting logic arises from the biology of inflammation. Common NSAIDs work by blocking enzymes COX-1 And COX-2essential for the production of prostaglandins. These substances fuel the inflammatory process but also perform fundamental physiological functions, such as protecting the gastric mucosa, regulating blood flow and maintaining cardiovascular balance. It is precisely this dual function that explains why an effective drug against pain can simultaneously increase the risk of ulcers, bleeding or cardiovascular events. The researchers then chemically modified the celecoxibone of the best known selective inhibitors of COX-2, transforming it into a photosensitive molecule. The new compounds they change shape when exposed to light. In one configuration they are relatively inactive; in the other they become much more effective at selectively inhibiting COX-2. In practice, the light acts as an external command that turns the drug on or off, allowing extremely precise control of the therapeutic effect both in time and space. It is a paradigm shift compared to traditional pharmacology. Until now, the doctor chose the dose, frequency and route of administration, but once the medicine was taken the control ended. With the photopharmacologyhowever, the activity of the molecule can theoretically be regulated even after administration, limiting it exclusively to the tissue affected by inflammation and reducing the exposure of the entire organism. Of course, this is not yet a technology ready to enter hospitals or pharmacies. In fact, all published work concerns the phase preclinicalbut it represents a particularly robust proof of principle because it demonstrates that an anti-inflammatory drug can indeed be controlled by an external physical stimulus without losing its biological efficacy.
How photopharmacology works: the drug lights up only where the light reaches
The heart of the research is represented by photopharmacologya discipline born just over a decade ago that aims to control the behavior of drugs through physical stimuli, in particular light. Unlike traditional controlled release systems, here it is not the medicine that is slowly released into the body, but its own biological activity that can be modulated in real time. The molecule is designed to change its structure when it is illuminated with a specific wavelength: one conformation is little or not at all active, the other acquires a high affinity for the therapeutic target. In the case of the new ones photocoxibthe target remains the enzyme COX-2responsible for the production of prostaglandins that fuel pain and inflammation. The difference compared to the anti-inflammatories available today is that the active ingredient could be “turned on” exclusively in the body area to be treated. This means that an inflamed joint, a damaged tendon or tissue undergoing surgery could receive much more targeted therapy, leaving the rest of the body exposed to minimal amounts of active drug. The clinical implications are potentially enormous. THE NSAIDs they are among the most prescribed medicines in the world, but their chronic use is limited by their side effects. According to numerous international guidelines and the recommendations of the main scientific societies, the risk of gastric ulcer, digestive bleeding, kidney damage and cardiovascular complications increases especially in elderly patients or in those who take anti-inflammatories for long periods. Reducing the systemic activity of the drug while maintaining its local efficacy would therefore represent one of the main objectives of modern pharmacology. The experiments published by the research group show that the new compounds are indeed able to modify their activity in response to light and to selectively inhibit the COX-2 in the “active” configuration. This is not yet a clinical demonstration in humans, but a preclinical result that confirms the feasibility of this approach. It’s the so-called proof of concepta proof of principle that paves the way for the development of increasingly sophisticated molecules. Of course, major technological hurdles still exist. The light must be able to reach the tissue to be treated and this makes it easier to imagine an application in superficial locationssuch as skin, joints or tissues accessible during surgical or endoscopic procedures. However, it will be more complex to treat deep organs, where optical fibers will be needed, miniaturized devices or molecules sensitive to wavelengths capable of penetrating biological tissues more effectively.
From research to patients: what are the prospects and limits of the new generation of anti-inflammatories
The enthusiasm aroused by these results is understandable, but the authors themselves urge caution. The path that separates a laboratory discovery from a drug available in hospital is long and requires numerous development phases: toxicological studies, advanced animal testing, phase I, II and III clinical trials, regulatory evaluations and finally the authorization of the drug agencies. It will therefore take years before we understand whether i photocoxib will actually be able to enter clinical practice. The research, however, is part of a much larger trend that is changing the way medicines are designed. Contemporary medicine focuses less and less on drugs that act indiscriminately on the entire organism and more and more on therapies intelligentcapable of being activated only at the time and place where they are needed. The same principle already guides other emerging technologies, such as some delivery systems with nanoparticlesdrugs activated by enzymes present in the tumor and precision medicine strategies. For chronic inflammatory diseases, from arthrosis to rheumatological pathologies, up to post-operative pain controla technology of this type could radically change the relationship between efficacy and safety. It would not eliminate the need to use anti-inflammatories, but it could make them much more selective, reducing the amount of side effects that today represents the main limitation of their use.
